RegulatoryCNBC-TV18
Caplin Point shares decline after USFDA OAI classification
Negative-67
GreyOak summary
Caplin Point Laboratories reported that the USFDA classified its Gummidipoondi facility as 'official action indicated' following an inspection. The company stated it does not expect a material impact on financials or operations. Shares declined 2.1% to ₹2,298 despite the firm's recent 15.3% net profit growth.
What it affects
- Caplin Point LaboratoriesCAPLIPOINTNegative -67
USFDA classified facility as official action indicated.Rolling sentiment Negative -44
Source
Read the original at CNBC-TV18More Caplin Point Laboratories news
- Caplin Point US own-label sales to double by 2026-27CNBC-TV18 · Company update ·
- Caplin Point Q2 revenue up 18%, stock falls 6%CNBC-TV18 · Results ·